Actionable news
0
All posts from Actionable news
Actionable news in FLXN: FLEXION THERAPEUTICS Inc,

Confidential treatment order

> begin 644 filename1.pdf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m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

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Flexion Therapeutics makes a similar move, sign up!

Other recent filings from the company include the following:

Flexion Therapeutics releases salary data. CEO sees compensation rise 13% - April 26, 2016

Flexion Therapeutics Announces Presentation Of Results FROM PIVOTAL PHASE 2B AND PHASE 3 CLINICAL TRIALS FOR ZILRETTA AT OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 2016 WORLD CONGRESS - April 4, 2016